|
Last Updated: Nov 18, 2006 - 12:32:53 PM |
Latest Research
:
Pharmacology
:
Surfactants
:
Lucinactant
Surfaxin (Lucinactant) Granted Orphan Drug Designation
Discovery Laboratories, Inc. (Nasdaq: DSCO), today announced that the Office of Orphan Products Development of the United States Food and Drug Administration has granted orphan drug designation to Discovery's lead product, Surfaxin(r), for the treatment of Bronchopulmonary Dysplasia (also known as Chronic Lung Disease, CLD) in premature infants.
Oct 29, 2005 - 4:49:00 PM
<< prev
next >>
|